Skip to main content

Table 1 The demographic features and NfL concentration in Cohort A and B

From: Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3

Group

Cohort A

Cohort B

Control

SCA3

Control1

Preclinical SCA3

Control2

Manifest SCA3

n

9

17

21

26

70

90

Age

54.33 ± 11.69

49.88 ± 11.75

31.62 ± 11.61

31.38 ± 9.30

43.13 ± 12.66

43.90 ± 12.16

Sex (M/F)

4/5

6/11

8/13

9/17

31/39

41/49

Expanded CAG repeats

N/A

73.18 ± 3.64

N/A

72.62 ± 4.97

N/A

73.91 ± 4.04

SARA

N/A

13.82 ± 5.56

N/A

0.73 ± 0.83

N/A

11.72 ± 6.02

ICARS

N/A

35.00 ± 11.06

N/A

1.81 ± 1.81

N/A

29.04 ± 13.90

Disease duration (ys)

N/A

5.82 ± 3.56

N/A

N/A

N/A

6.59 ± 5.53

Total intracranial volume (mL)

N/A

N/A

N/A

1416.00 ± 128.60 (n = 2)

N/A

1496.00 ± 231.20 (n = 66)

Cerebellum (mL)

N/A

N/A

N/A

148.17 ± 87.77 (n = 2)

N/A

127.07 ± 21.27 (n = 66)

Brainstem (mL)

N/A

N/A

N/A

22.17 ± 1.38 (n = 2)

N/A

20.05 ± 4.66 (n = 66)

Serum NfL (pg/mL)

9.10 ± 3.29

41.50 ± 14.78

6.88 ± 2.72

15.03 ± 7.49

9.07 ± 6.02

37.56 ± 13.47

CSF NfL (pg/mL)

471.70 ± 210.40

4262.00 ± 1762.00

N/A

N/A

N/A

N/A

  1. Values are mean ± SD. SARA Scale for the assessment and rating of ataxia, ICARS International cooperative ataxia rating scale, N/A Not applicable